The following list some of the top traded US stocks, not in any order of ranking, by our POEMS clients along with major news announced on the stocks in the month of June.
At a glance:
- The month of June was volatile for all three major indices following the release of higher-than-estimated ADP non-farm payrolls, which shows data collected from private enterprises, FOMC statements and the Fed Funds rate, all of which spooked inflation fears. All three major indices dipped in the first half of the month before recovering in the second half.
- Fed Funds rates are unchanged but there has been a shift in the Fed’s economic projections. The Fed now indicates not one but two interest-rate hikes in 2023.
- Bears also beat a dramatic retreat1 on the back of a consistent strong economic recovery.
The three US major indices – Dow Jones, S&P 500 and Nasdaq Composite – retreated in the first half of the month. The Dow dropped by 3.79% from 34,584.19 points to a low of 33,271.93 points, the S&P 500 shed 1.24% from 4,216.52 to 4,164.40 while Nasdaq Composite gave up 2.03% from 13,829.06 to a low of 13,548.93. The declines were spooked by tapering fears caused by inflation, when ADP non-farm jobs rose 978K, 51.63% better than the estimate of 645K at the start of the month of June. However, the fears diminished when the non-farm employment change was released 2 days later after the release of ADP non-farm payroll, a change at 559K, 13.33% below the estimate of 645K.
Towards the middle of the month, the Fed kept its Fed Funds rate unchanged at 0.25%. However, the FOMC projects that there will be two rate hikes in 2023 after possible tapering. Following an initial knee-jerk reaction, all three major indices managed to recover.
The Dow closed at 34,502.52, S&P 500 at 4,343.53 and Nasdaq Composite at 14,503.95 – a recovery of 3.70%, 3.20% and 7.05% respectively from their month lows. This could be due to the Fed’s indication that it will maintain its easy monetary policy for now. Tapering may also be out of the picture in the short term as the FOMC meeting remained inconclusive on this.
We have included technical charts for all the 10 counters. Charts are analysed on different time frames. The charts are for your information only and the support and resistance levels discussed are solely based on our dealers’ views. The technical charts should not be constituted as buy or sell recommendations and investors/traders are advised to do their own due diligence before making any trade.
Here are some of June’s top traded US stocks on Phillip’s Online Electronic Mart System (POEMS), based on gross market value traded.
Coinbase Global Inc (NASDAQ: COIN)
Coinbase went from an astonishing opening price of US$304 to a closing price of US$236.54, a 22.19% drop in the month of May. This followed an announcement by Elon Musk, an outspoken supporter of bitcoins who have invested US$1.5bn in the cryptocurrency2, that Tesla (NASDAQ: TSLA) was no longer accepting bitcoins as payment. He reasoned that mining bitcoins is too harsh on the environment3. Shortly after, he reversed his position and said Tesla would accept bitcoin payments again once mining becomes more energy-efficient4. In June, COIN hovered between US$210 and US$250. Its drop mirrored the market’s overall consolidation due to uncertainties over the big dropped in May5.
There might be potential for COIN to rally again on the back of approval to offer crypto custody services in Germany. This might allow COIN to expand its market to generate more sales. Together with MicroStrategy (MSTR.US) who added US$489mn of bitcoins to its balance sheet,6 the stocks of companies like COIN which deal with cryptocurrencies may be supported.
Citigroup (NYSE: C)
Citi started dropping from a high of US$80.29 in June. This could be due to its resistance level at the price of US$80, as seen in 2018 and 2020. Citi dropped from that price as investors might have decided to take profits.
Later in the month, it dwindled further to US$67.13, down 16.39% from its high. This was after a warning from Mark Mason, Chief Financial Officer, that trading revenues may disappoint in Q2 2021 as trading activities moderated.7
However, Citi managed to rebound to close at US$70.89, a 5.6% increase from its low as the Fed allowed banks to resume dividends and shares buyback previously restricted during the COVID-19 pandemic.8 The news gave investors cheer on the whole financial sector.
Plug Power Inc (NASDAQ: PLUG)
PLUG managed to touch US$36.04 on 30 June 2021, up 17.04% from an opening price of US$31.10. This might be credited to a report on the fuel-cell market, which projects that the market will reach US$14.6bn by 20279, up 5,451% from 2020. The USD$263million estimated market size10 may have encouraged investors to look at fuel-cell companies like PLUG.
Later in the month, news that the US has returned to the Paris Climate Agreement and the Biden administration’s push for greener energy infrastructure led to interest in hydrogen fuel-cell companies like PLUG.11 US support for the Paris Agreement is crucial, as the US is one of the top carbon emitters globally. Hydrogen fuel cells are part of clean energy and investors are hoping that PLUG may benefit from a potential increase in business and earnings.
Clean Energy Fuels Corp (NASDAQ: CLNE)
In the same industry as PLUG is Clean Energy. Clean should benefit from the report on the fuel-cell sector as well, that global sales could rise to US$14.6bn by 2027.12 Clean Energy’s shares were up 27.03% from their opening price of US$7.99 to close at US$10.15.
Clean’s prospects have brightened on the back of a 5-year agreement it just signed with Amazon to provide renewable natural gas. The second piece of good news is Chevron’s US$20mn investment in the company.13 Both the companies are big boys in their industries and the partnerships are expected generate more revenue for Clean to fund its expansion.
Status: Technical Sell below US$10.30
Bearish market structure
Xpeng Inc (NYSE: XPEV)
Xpeng rallied 31.81% from its opening price of US$33.70 to US$44.42 in June. This followed its announcement that it delivered 13,340 vehicles in Q1 2021, a 487% jump from the previous year’s 2,27114, fuelling confidence in Xpeng’s outlook.
Its President, Brian Gu, was also positive that Q2 sales could exceed the company’s delivery targets as demand for Chinese EVs remains strong.15 To support its growth ambitions, Xpeng raised US$1.8bn from a Hong Kong dual primary listing recently. It started trading on 7 July 2021. The funds raised could potentially be used a war chest for further growth. Its dual listings mean Xpeng can raise funds both on the HKEX and NYSE.
Sundial Growers Inc. (NASDAQ: SNDL)
Sundial is a legal cultivator and distributor of cannabis in Canada. It came into the spotlight this month thanks to Reddit. The stock opened at US$1.03, before a short squeeze pushed it up to US$$1.49. It closed the month at US$$0.94.
For the first time, Sundial managed to report a positive adjusted EBITDA in Q2. This marked an important corporate milestone. The profits came from streamlining its business and cutting costs.
However, the declines in its gross revenue over the quarters are worrying. Sundial may be losing market share as it has slashed its sales and marketing costs by nearly half. Another risk is the recent change in its products19. It has changed its core business from selling marijuana to cannabis. Moving forward, Sundial will need to figure out ways to establish its foothold in the new market.
Although Sundial’s consumers are mainly based in Canada, it is widely expected to expand to the US. There is growing support for cannabis legalisation at the federal-government level in the US.2021 This brings hope that there will opportunities for growth in the cannabis industry.
Status: Technical Sell below US$1.00
Tilray Inc. (NASDAQ: TLRY)
Another weed company made popular by Reddit is Tilray. Its share price was driven up at the beginning of June to a high of US$23.04. Between opening at US$17.13 and closing at US$18.08, Tilray yielded a gain of around 5.5%.
Tilray recently merged with another pot company to form the world’s largest weed company by revenue.22 Similar to Sundial, Tilray has benefited from budding support for legalising cannabis in the US. Legalisation means more sales.
As the merger was recent, there is not much data to prove if it is actually beneficial. However, the merger did give birth to a new medical cannabis brand, Symbios23. This new product line is aimed at providing a more comprehensive line of products to medical patients. With a growing cannabis market24 and the new line of product, Tilray is worth keeping an eye on.
Status: Technical Sell below US$16.68
Bearish movement into immediate support
Fuelcell Energy Inc. (NASDAQ: FCEL)
Fuelcell Energy develops fuel cells for use as alternative fuel. In June, the stock surged to a high of US$$12.62 before crashing to US$8.43. The fall could be blamed on a surprise dip in its Q2 revenue25. The market was expecting a loss per share of 5 cents but Fuelcell’s loss came in at 6 cents.
Nonetheless, alternative fuels are gaining traction as ESG grows in importance26. Clean energy will be highly sought after as firms look for ways to reduce carbon footprints. President Biden’s aim to cut greenhouse gas pollution by 203027 should further stimulate the industry.
The risk now lies in Fuelcell’s ability to sustain its business. Current infrastructure works on traditional fossil fuels. Converting and upgrading infrastructure that runs on clean energy require resources and years of development. Investors are likely to question if Fuelcell is able to tide through till the mass adoption of alternative fuels.
Status: Technical Buy above US$8.00
As long as its immediate support holds, share price could be range-bound towards its immediate resistance above.
Torchlight Energy Resources. (NASDAQ: MMAT)
Torchlight Energy (TRCH) merged with Meta Materials (MMAT) on 26 June 2021. TRCH will undertake a reverse stock split of 1 for 2, followed by a change in its corporate name and stock ticker28. From 28 June 2021, the company will trade under the name of Meta Materials Inc.
Torchlight is another popular meme stock that had a roller-coaster month. Its lowest point in June was at US$5.80, after the stock hit a high of US$21.70. Investing in meme stocks entails high risk as their share prices may rise and fall equally quickly.
After the merger, management intends to move away from oil and gas to developing high-performance functional materials and nanocomposites29. Nanotechnology is the next new thing, with its global market expected to reach US$70.7bn by 202630. Nanomaterials can be used in multiple industries, including construction, healthcare and agriculture31. This implies substantial growth potential. Downside lies with research and development capabilities. Torchlight risks lagging the other firms if its R&D is weak. However, looking at the 64 pending global patents it has filed for, its R&D capability should not be much of a concern.
Status: Technical Sell below US$6.30
Bullish market structure into support, more potential down moves once below
ORPHAZYME – ADR (NASDAQ: ORPH)
Orphazyme was one of the more volatile stocks in our list. Wall Street Bets subscribers led a short squeeze on the stock in June, fuelling a surge to a 52-week high of US$$77 on 10 June 2021. Like most meme stocks after the squeeze, Orphazyme crashed to around US$10 over the next few days.
On 15 June 2021, one of Orphazyme’s major shareholders liquidated his shares. This gave rise to hopes of a potential merger32 and its shares broke out of their US$10 range.
Gains from the rumours were soon erased by the US Food and Drug Administration’s (FDA) rejection of Orphazyme’s key drug candidate for a metabolic disease, Niemann Pick C.33. With no other projects to back its prospects, Orphazyme had to cut its revenue forecasts.
Investing in biopharmaceutical firms entails a considerable level of risk. In the sector, failure rates on inventions are 85-95%34. Risks are compensated if the drugs take off, in which case investments can possibly grow 200-300% in a single day. Investors are advised to assess their risk appetites before investing in such stocks.
Status: Technical Buy above US$7.35
Click here to open a POEMS trading account
Important Information: This report is prepared and/or distributed by Phillip Securities Research Pte Ltd (“Phillip Securities Research”), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgement. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES Where the report contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.
If Distribution is to Australian Investors This report is produced by Phillip Securities Pte Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services License No. 246827). This report contains general securities advice and does not take into account your personal objectives, situation and needs. Past performance is not a reliable indicator of future performance. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.